The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naïve Rheumatoid Arthritis: A Network Meta-Analysis

The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naïve Rheumatoid Arthritis: A Network Meta-Analysis

Background: The mainstream medications for rheumatoid arthritis (RA) include conventional disease-modifying antirheumatic drugs (cDMARDs), which mostly are methotrexate (MTX), and biologic agents such as adalimumab (ADA), certolizumab (CZP), etanercept (ETN), golimumab (GOL), infliximab (IFX), and t...

Full description

Bibliographic Details
Main Authors:	Weiyan Cai, Youyi Gu, Huanqin Cui, Yinyin Cao, Xiaoliang Wang, Yi Yao, Mingyu Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-03-01
Series:	Frontiers in Pharmacology
Subjects:	rheumatoid arthritis DMARDs safety efficacy network meta-analysis
Online Access:	http://journal.frontiersin.org/article/10.3389/fphar.2018.00138/full

Similar Items

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021-06-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
by: Basant Kumar Maheshwari
Published: (2018-01-01)

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
by: Basiru Ahmad Zago, et al.
Published: (2020-12-01)

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
by: Yuji Nozaki
Published: (2021-05-01)

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
by: Cédric Lukas, et al.
Published: (2019-11-01)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
by: Vandana Bhushan, et al.
Published: (2021-09-01)

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
by: Thomas Wilke, et al.
Published: (2017-08-01)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
by: Soo-Kyung Cho, et al.
Published: (2017-12-01)

DMARDs–Gut Microbiota Feedback: Implications in the Response to Therapy
by: Oscar Zaragoza-García, et al.
Published: (2020-10-01)

Rheumatoid arthritis
by: Yoshiya Tanaka
Published: (2020-09-01)

CORRELATIONS BETWEEN SYSTEMIC THERAPY WITH CONVENTIONAL (SYNTHETIC) AND BIOLOGICAL DMARDS, RHEUMATOID ARTHRITIS AND PERIODONTAL INDICES OF CHRONIC PERIODONTITIS
by: Maria Alexandra Martu, et al.
Published: (2019-01-01)

Management of rheumatoid arthritis during pregnancy: challenges and solutions
by: Krause ML, et al.
Published: (2016-03-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)

The importance of early arthritis in patients with rheumatoid arthritis
by: Georgiana Iftimie, et al.
Published: (2018-10-01)

Rheumatoid arthritis and lymphoma: the role of disease-modifying anti-rheumatic drugs
by: Detrick, Jordan
Published: (2018)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
by: Mark C. Genovese, et al.
Published: (2020-06-01)

Clinical and Laboratory Associations with Methotrexate Metabolism Gene Polymorphisms in Rheumatoid Arthritis
by: Leon G. D’Cruz, et al.
Published: (2020-09-01)

The Use of Tocilizumab in Combination with Methotrexate in Indonesian Rheumatoid Arthritis Patients (PICTURE INA Study)
by: Bambang Setyohadi, et al.
Published: (2018-06-01)

Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
by: Akhlaghi S, et al.
Published: (2018-10-01)

Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis
by: Yannick Degboé, et al.
Published: (2020-06-01)

Rheumatoid Arthritis-associated Interstitial Lung Disease in Greece: A Multicentre Epidemiological and Clinical Study
by: Theofanis Karageorgas, et al.
Published: (2018-01-01)

BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study
by: Fiona Rayner, et al.
Published: (2021-07-01)

Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview
by: Yoshiya Tanaka
Published: (2021-03-01)

Investigation of the plasma levels of CCL-17 and CCL-25 and their receptor gene expression in rheumatoid arthritis patients
by: Zahra Samimi, et al.
Published: (2019-07-01)

Investigation of the plasma levels of CCL-17 and CCL-25 and their receptor gene expression in rheumatoid arthritis patients
by: Samimi Z, et al.
Published: (2019-07-01)

Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis
by: D. Vinson, et al.
Published: (2020-04-01)

Treatment of Rheumatoid Arthritis with Methotrexate Alone or A Combination of Methotrexate and Hydroxychloroquine
by: Natharubini Nadarajah, et al.
Published: (2016-09-01)

A Systematic Review to Identify the Effects of Biologics in the Feet of Patients with Rheumatoid Arthritis
by: Laura Ramos-Petersen, et al.
Published: (2021-12-01)

Sustained drug-free remission and persistent hypogammaglobulinemia in a patient with rheumatoid arthritis three years after discontinuing Rituximab treatment
by: Marco Krasselt, et al.
Published: (2021-04-01)

Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
by: Roy Fleischmann, et al.
Published: (2019-10-01)

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
by: Shuzo Sato, et al.
Published: (2021-08-01)

Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
by: José A. Sacristán, et al.
Published: (2019-10-01)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
by: Janet E. Pope, et al.
Published: (2019-04-01)

The effect of disease modifying drugs on the lung in patients with rheumatoid arthritis
by: Tashfeen Mahmood, et al.
Published: (2016-01-01)

“Living a normal life”: a qualitative study of patients’ views of medication withdrawal in rheumatoid arthritis
by: Kenneth F. Baker, et al.
Published: (2019-06-01)

Patterns of Response to Different Treatment Strategies in Seropositive Rheumatoid Arthritis Patients in a Tertiary Hospital in South‐Western Saudi Arabia: A Retrospective Study
by: AlOmair M, et al.
Published: (2021-08-01)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
by: George W. Reed, et al.
Published: (2019-11-01)

ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation
by: Debbie M. Boeters, et al.
Published: (2019-05-01)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
by: Krzysztof Bonek, et al.
Published: (2021-02-01)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
by: Paul Emery, et al.
Published: (2020-05-01)